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doi:10.1Objectives: This study tested the hypothesis that monocyte chemotactic protein 1 (MCP1) is required for
abdominal aortic aneurysm(AAA)and smoothmuscle phenotypicmodulation in amouse elastaseperfusionmodel.
Methods: Infrarenal aortas of C57BL/6 (wild type [WT]) and MCP1 knockout (KO) mice were analyzed at 14
days after perfusion. Key cellular sources of MCP1 were identified using bone marrow transplantation. Cultured
aortic smooth muscle cells (SMCs) were treated with MCP1 to assess its potential to directly regulate SMC
contractile protein expression and matrix metalloproteinases (MMPs).
Results: Elastase perfused WT aortas had a mean dilation of 102% (n ¼ 9) versus 53.7% for MCP1KO aortas
(n¼ 9, P<.0001) and 56.3% forWT saline-perfused controls (n¼ 8). Cells positive for MMP9 andMac-2 were
nearly absent in the KO aortas. Complimentarily, the media of the KO vessels had abundant differentiated
smooth muscle and intact elastic fibers and markedly less MMP2. Experiments in cultured SMCs showed
MCP1 can directly repress smooth muscle markers and induceMMP2 andMMP9. Bone marrow transplantation
studies showed that KO ofMCP1 in bone marrow–derived cells protects from AAA formation. Moreover, KO in
the bone was significantly more protective than global KO, suggesting an unexpected benefit to selectively
depleting MCP1 in bone marrow–derived cells.
Conclusions: These results have shown that MCP1 derived from bone marrow cells is required for experimental
AAA formation and that retention of nonbone marrow MCP1 limits AAA compared with global depletion. This
protein contributes to macrophage infiltration into the AAA and can act directly on SMCs to reduce contractile
proteins and induce MMPs. (J Thorac Cardiovasc Surg 2011;142:1567-74)The etiology of aortic aneurysms (AAs) is thought to be
a complex interplay among the vessel wall, innate immune
cells, and the adaptive immune system.1 The predominant
histologic hallmarks of AAs include the presence of an
abundant inflammatory infiltrate and the upregulation of
proteases, including matrix metalloproteinase (MMP)2
and MMP9.1 These enzymes play an essential role in AA
by destruction of collagen and elastin, thereby weakening
the vessel wall. Bone marrow–derived cells are the required
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Sessential contributor of MMP2, indicating that both are
active participants in AA pathogenesis.2-4
Our laboratory has recently shown that phenotypic
modulation of smooth muscle cells (SMCs), as defined by
coordinate downregulation of multiple SMC-selective con-
tractile proteins, occurs within experimental abdominal
AAs (AAAs).5 This is complimented by human genetic
studies suggesting genetic defects in SMC contractile pro-
teins underlie thoracic aortic aneurysms.6 Although con-
tractile proteins are key to anchoring cells to matrix, the
exact mechanismswhereby their genetic defect or transcrip-
tional downregulation leads to an AA has not been defini-
tively identified. Nevertheless, data strongly suggest the
importance of proper SMC contractile protein expression.
Evidence fromother vascular diseases suggests thatmacro-
phages and other circulating cells are important sources of
ligands capable of altering contractile protein expression.7-11
In contrast, the SMC is becoming increasingly recognized as
an important contributor to the inflammatory milieu.12 There
is therefore evidence to suggest that leukocyte infiltration and
SMC phenotypic modulation within AAAs might be interre-
lated and, potentially, interdependent processes key to AAA
formation.
Although this interplay between SMC phenotypic
changes and macrophage recruitment is likely complex, ev-
idence suggests C-C chemokine monocyte chemotacticdiovascular Surgery c Volume 142, Number 6 1567
Abbreviations and Acronyms
AAs ¼ aortic aneurysms
AAA ¼ abdominal aortic aneurysm
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IL-1b ¼ interleukin-1b
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SmaA ¼ smooth muscle a-actin
SMCs ¼ smooth muscle cells
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Sprotein 1 (MCP1) might regulate both leukocyte recruit-
ment and the SMC phenotype. Its interaction with CCR2,
a G-protein coupled receptor whose ligands include
MCP1, MCP3, and MCP5, has been shown to be essential
for the recruitment of monocytes in response to various
pathogens.13,14 Interestingly, MCP1 has been shown to
directly promote SMC migration15 and to induce tissue fac-
tor,16 even in the genetic absence of CCR2. Taken together,
this suggests MCP1 might be a crucial determinant of AAA
macrophage and SMC content and, therefore, might play
a major role in disease progression.
Although there has not been a direct study of MCP1 in
AAAs, seemingly controversial results have been obtained
from investigations into the role of CCR2. Specifically, in
experimental models, knockout of CCR2,17 leukocyte tar-
geted knockout by way of bone marrow transplant,18 and
small interferingRNAknockdown ofCCR2 in leukocytes,19
all significantly inhibit AAAs. However, depleting CCR2’s
ligands using dominant negative CCR2 resulted in an appar-
ent increase in aortic diameter.19 Given these apparently
conflicting results, compounded by the existence ofmultiple
ligands for CCR2 and the ability of MCP1 to act in CCR2’s
genetic absence,16 there is a clear need to definitively ad-
dress the role of MCP1 in AAAs. We aimed to resolve this
deficiency using genetic knockout and delineate the cellular
source ofMCP1 inAAAusing bonemarrow transplantation.METHODS
Elastase Perfusion Model of Aneurysm Formation
C57BL/6 and MCP1KO mice13 were obtained from the Jackson
Laboratory (Bar Harbor, Me). All KOs were on a C57BL/6 background.
The AAA model used has been described previously.5,20 In brief, the
procedure includes in situ isolation of the abdominal aorta, cannulation,
and perfusion of 0.47 U/mL porcine pancreatic elastase (Sigma-Aldritch,
St. Louis, Mo) for 5.5 minutes. Control wild type (WT) mice were
perfused with 0.9% normal saline. AAAs develop reproducibly 14 days
after elastase perfusion in the WT mice and none developed in the
saline-perfused controls. All procedures were performed with the surgeon
unaware of the identity of themice using an elastase solution prepared from
Sigma lot no. 078K7018. All animal procedures were in accordance with
University of Virginia Animal Care and Use Committee Protocol 3634.1568 The Journal of Thoracic and Cardiovascular SurHistology and Immunohistochemistry
The extracted aortas were paraffin embedded and cut into 5-mmsections.
In brief, after antigen retrieval (Vector Laboratories, Burlingame, Calif)
with a pressure cooker, the primary antibodies were bound and detected us-
ing the VectaStain Elite Kit. The antibodies used were MMP9 (R&D Sys-
tems, Minneapolis, Minn), smooth muscle a-actin (SMaA) (Dako,
Carpentaria, Calif), MCP1 (Santa Cruz Biotechnology, Santa Cruz, Calif),
and Mac-2 (Cedarlane Laboratories, Burlington, NC). Visualization was
done with diaminobenzidine (Dako) for MMP9, MCP1, and Mac-2, and
Cy-3 (Sigma Aldrich) for SMaA. Counter staining was done using Harris
Hematoxylin 1 (Richard-Allen Scientific, Kalamazoo, Mich). Negative
controls were run with the primary antibody omitted. Histochemistry was
performedusing amodifiedRussel-Movat pentachromemethod tovisualize
the elastic fibers. Images were acquired using the 103 objectives on a Zeiss
microscope equipped with an AxioCam digital camera using the AxioCam,
version 4.6, software program.
Smooth Muscle Culture and Reagents
Rat aortic SMCswere cultured as previously described.21 The cells were
grown to confluence and serum starved for 3 days before treatment with
MCP1 (PeproTech, Rocky Hill, NJ) for 24 hours. RNAwas harvested using
Trizol Reagent (Invitrogen, Carlsbad, Calif), and quantitative polymerase
chain reaction (qPCR) performed to quantify SmaA, SM22a, and SM-
MHC mRNA, as described previously.10 The primers used to detect
MMP2 were 50- catcgctgcaccatcgcccatcatc and 50-cccagggtccacagctcatcat
catcaa and those for MMP9 were 50-agctgactacgacacagacagaa and
50-ggccctcgaagatgaatggaaat.
Bone Marrow Transplantation
Six-week-old WT (n ¼ 9) and MCP1KO mice (n ¼ 6) were sublethally
irradiated with 2 separate exposures of 650 mCu radiation 3 hours apart.
Bone marrow was extracted from the femur and tibia of 2 WT and 2
MCP1KO mice by flushing with sterile Dulbecco’s phosphate buffered sa-
line; 23 106 cells were injected into the tail vein of the irradiated hosts im-
mediately after the second irradiation. The mice were allowed to recover
for 6 weeks before elastase perfusion. Depletion of the host bone marrow
by irradiation was documented by not injecting cells into the irradiated
mice of both genotypes and observing lethality. The identity of the mice
before reconstitution was confirmed using qPCR genotyping protocols
(available from: jaxmice.jax.org) for the MCP1KO transgene. All mice
were killed 14 days after elastase perfusion, and the aortas were processed
for histologic examination. The peripheral blood cells and peripheral aortic
tissuewere isolated after bonemarrow transfer and analyzed using qPCR to
confirm successful and complete reconstitution.
Human Tissue Collection
Human AAA tissue was collected according to the University of
Virginia institutional review board protocol 13178. All patients pro-
vided preoperative consent. AAA tissue was resected at open surgical
AAA repair, and tissue was obtained from the ascending aorta by aortic
punch from patients undergoing coronary artery bypass grafting as
a control. The harvested tissues were fixed in 4% paraformaldehyde
for 24 hours, processed, and embedded in paraffin. The control tissue
was collected only from patients without a history of collagen vascular
disease or aneurysms and without evidence of atherosclerosis in the as-
cending aorta.RESULTS
MCP1 Increased in Mouse and Human AAAs
To confirm MCP1’s presence in AAAs, we first analyzed
WT mouse aortas 14 days after elastase or saline perfusion.gery c December 2011
FIGURE 1. Monocyte chemotactic protein 1 (MCP1) is increased in abdominal aortic aneurysm (AAA) and required for disease progression. A, Immu-
nohistochemistry performed 14 days after surgery indicates MCP1 is upregulated in elastase-perfused AAAs compared with saline-perfused controls.
B, MCP1 more abundant in tissue from patients undergoing open aneurysm repair than in control aorta from patients undergoing coronary artery bypass
grafting (CABG). Wild type (WT) aortas perfused with elastase (black squares) show significantly greater change in aortic diameter than MCP1KO aortas
perfused with elastase (black triangles) at 14 days (P<.0001). C, MCP1KO aortas statistically indistinguishable fromWTaortas perfused with saline (black
diamonds).




SMCP1was markedly elevated by immunohistochemistry 14
days after elastase perfusion compared with the age-
matched, saline-perfused control aortas (Figure 1, A). Sim-
ilarly, MCP1 protein was significantly more abundant in the
aortas from patients undergoing open aneurysm repair than
in the nonaneurysmal control aortas (Figure 1, B). These
data confirm previous reports of increased MCP1 produc-
tion in human22 and mouse23 AAAs and highlight the
potential importance of MCP1 in experimental and human
AAAs.
MCP1KO Mice Resistant to Experimental AAA
MCP1KO mice were obtained on a C57Bl/6 background
from the Jackson Laboratory.13 The baseline aortic diame-
ters were equivalent for WT and MCP1KO mice, and no
overt signs of developmental vascular differences were
present. The MCP1KOmice subjected to elastase perfusion
did not form aneurysms and exhibited a mean aortic dilation
of 53.7%, a significant reduction compared with the 102%
increase in the age-matched WT mice after elastase perfu-
sion (P < .0001). Moreover, the mean dilation of the
MCP1KO mice was similar to the 56.3% observed in the
saline-perfused WT mice (Figure 1, C). It is important to
note that the dilation seen in the saline controls, which
was related to the mechanical disruption during perfusion,
was similar to that seen in previous studies.5 These results
indicate that MCP1 is required for AAA formation after
elastase perfusion.The Journal of Thoracic and CarMCP1KO Mice Exhibited Near Absence of Mac2 or
MMP9-Positive Cells After Elastase Perfusion
Given the role of MCP1 in monocyte chemotaxis, we hy-
pothesized one mechanism by which MCP1KO prevents
AAA formation would be through inhibiting macrophage
infiltration. The results of the immunohistochemistry
analyses 14 days after elastase perfusion showed markedly
reduced expression of Mac-2, a macrophage surface maker,
in the elastase-perfused MCP1KO mice. This is in stark
contrast to theWTmice, in whichMac-2 staining was abun-
dant within the medial and adventitial layers of the vessel.
Furthermore, levels of the potent, pro-inflammatory cyto-
kine interleukin-1b (IL-1b) was markedly reduced in the
vessel wall of the MCP1KO mice (Figure 2, A). Thus, it ap-
pears MCP1 signaling contributes to monocyte recruitment
and IL-1b production 14 days after elastase perfusion.
Because bone marrow–derived cells have been shown to
be the key source of MMP9 within experimental AAAs,24
we further hypothesized that the inhibition of macrophage
infiltration seen in the MCP1KO mice would be associated
with a reduction of MMP9. Indeed, MMP9-producing cells
were almost absent in the aortas of the MCP1KO mice
(Figure 2, A). This indicates that MMP9 production in ex-
perimental AAAs occurs downstream of MCP1 signaling.
However, results do not distinguish whether MCP1-
mediated MMP9 production occurs by direct action on tar-
get cells and/or secondary to MCP1-dependent leukocyte
recruitment and chemokine production.diovascular Surgery c Volume 142, Number 6 1569
FIGURE 2. MCP1KO reduces inflammation and protects from medial degredation. Immunohistochemistry performed 14 days after elastase perfusion in-
dicated levels of Mac-2, interleukin-1b (IL-1b), and matrix metalloproteinase (MMP)9 are significantly reduced in MCP1KO aortas (left column) compared
withWTaortas (right column) 14 days after elastase perfusion. A, Intact elastic fibers, as detected byMovat pentachrome stain (black), and SMaA-express-
ing cells (red) are increased in MCP1KO mice compared with WT mice. B, In contrast, medial cells of MCP1KO mice produce significantly less MMP2
(brown) as measured by immunostaining.




SElastic Fibers and Differentiated SMCs Abundant in
Aortic Wall of MCP1KOs
Increased inflammatory characterization and MMP
production are thought to play major causative roles in
the elastic fiber degradation that is a major hallmark of
AAA.1 We next examined the extent to which MCP1KO
affects elastic fiber content. The aortas of the MCP1KO
treated with elastase had multiple intact layers of elastic fi-
bers at day 14, with little to no degradation observed accord-
ing to Movat pentachrome staining (Figure 2, B). Similarly,
SMaA staining was far more evident in the aortic wall of the
elastase-perfused MCP1KO than in the WT mice (Figure 2,
B), consistent with increased fully differentiated SMCs in
these vessels.
Because the SMC, or another nonbone marrow–derived
cell type,2 is the essential source of MMP2 within AAAs,
we further assayed MMP2 production in our tissues. Inter-
estingly, the cells in the media of MCP1KO mice were
almost universally negative for MMP2. This is a noticeable
contrast to the media of the WT mice (Figure 2, B).
Although the preceding data have established a role for
MCP1-dependent pathways in regulating SMC phenotype
and MMP2 production within AAAs, the data could not
distinguish whether MCP1 plays a direct or indirect role
in mediating these changes.1570 The Journal of Thoracic and Cardiovascular SurKnockout of MCP1 in Bone Marrow–Derived Cells
Prevented AAA Formation, Medial Degradation, and
Histologic Signs of Inflammation
Many AAA resident cell types have been shown to be ca-
pable of producing MCP1, including endothelial cells,
SMCs, fibroblasts, natural killer cells, natural killer T cells,
and macrophages. It is therefore uncertain whetherMCP1 is
predominantly produced by bone marrow–derived cells or
vessel wall resident cells. To address this, we lethally irra-
diated WT and MCP1KO mice and rescued them with
bone marrow from WT and MCP1KO donors. In all cases,
successful and complete reconstitution of the host bone
marrow and the identity of the host mice were validated us-
ing qPCR genotyping on peripheral blood cells and host tis-
sues isolated at harvest. The control experiments performed
with WT bone marrow transplanted into WT recipients
(WT/WT) and with MCP1KO bone marrow transplanted
into MCP1KO recipients (MCP1KO/MCP1KO) pro-
duced comparable results to those seen in nonirradiated
mice. Interestingly, theWTmice that received bone marrow
cells (BMCs) from MCP1KO mice (MCP1KO/WT) did
not develop AAAs after elastase perfusion. In contrast,
the MCP1KO mice that received BMCs from WT mice
(WT/MCP1KO) showed the development of AAAs sim-
ilar to the WT/WT mice (Figure 3).gery c December 2011
FIGURE 3. Mice lacking monocyte chemotactic protein 1 (MCP1) in
bone marrow do not form aneurysms after elastase perfusion. Wild type
(WT) mice with bone marrow cells (BMCs) donated from MCP1KO
mice (MCP1KO/WT) showed significant reduction in aortic dilation
14 days after elastase perfusion compared with WT mice with BMCs do-
nated from WT mice (WT/WT) or MCP1KO mice with BMCs donated
from WT mice (WT/MCP1; P< .0001). MCP1KO/WT mice also
showed significantly increased protection compared with mice with
MCP1KO BMCs transplanted into MCP1KO recipients (P ¼ .0088).




STo compliment these findings, the loss of MCP1 produc-
tion in the bone marrow–derived cells appears sufficient to
create a similar pattern of compositional changes in the ves-
sel wall to those seen in the conventional, nonirradiated
MCP1KO mice (Figure 2). Specifically, the MCP1KO to
WT mice had an intact SMaA-rich media with multiple in-
tact elastic fibers by Movat pentachrome staining and little
to no MMP2. This result is contrasted by the WT/WTand
WT/MCP1KO groups, which exhibit loss of elastic fibers
and SMaA expression. Similarly, the infiltration of macro-
phages and upregulation of MMP9 and IL-1b seen in both
the WT/WT and WT/MCP1KO groups are dramati-
cally reduced in the MCP1KO/WT mice (Figure 4).
Taken together, bone marrow–derived MCP1 appears cru-
cial for both AAA progression and a number of major
underlying compositional changes. These results indicate
that development of experimental AAAs is dependent on
MCP1 derived from BMCs and implies that the initial
step in recruitment of bone marrow–derived cells to
AAAs does not require MCP1, although MCP1 might
play a redundant role in this process.
There is evidence from these studies, however, that
MCP1 signaling plays a more complex role in AAA
progression than being purely detrimental. The mean aortic
dilation seen in the MCP1KO/WT group (15.9% 
6.2%) was significantly lower than that seen in the
MCP1KO/MCP1KO bone marrow transplantation group
(57. 8%  11.0%, P ¼ .009; Figure 3). This suggests that
production of MCP1 by nonbone marrow–derived cellsThe Journal of Thoracic and Carconfers an unexpected advantage in attenuating the devel-
opment of AAA. However, whether this relates to the cell
type producing MCP1, the cell type responding to MCP1,
the time at which MCP1 is produced by non-BMCs, or
the amount of MCP1 produced cannot be definitively con-
cluded from the existing data. Nevertheless, this ‘‘positive
contribution’’ of nonbone marrow–derivedMCP1 is a novel
and surprising observation and suggests that limited or se-
lective abrogation of MCP1 might be more therapeutically
beneficial than complete ablation.
MCP1 Represses Smooth Muscle Markers and
Activates MMP Production in Cultured SMCs
The results described thus far have demonstrated a role
for MCP1 in promoting macrophage infiltration and SMC
phenotypic modulation in elastase-induced aneurysms.
Although it possible that the effects on SMCs in vivo are in-
direct consequences of MCP1’s effects on the macrophage,
an unexplored possibility exists that MCP1 can directly reg-
ulate SMC differentiation and MMP production. Because
tested mouse SMC cultures exhibit variable expression of
SMC differentiation marker genes, we treated an estab-
lished rat SMC culture,21 previously published in mouse
vascular biology studies10 and consistently exhibiting
SMC marker expression with 0-, 0.5-, 5-, and 50-ng/mL re-
combinant MCP1. MCP1 repressed SMC differentiation
marker gene expression (SMaA, SM22, and SM-MHC) in
an apparently dose-dependent manner (Figure 5). In con-
trast, MCP1 induced both MMP2 and MMP9 expression
in these experiments, consistent with the possibility that
MCP1-mediated SMC phenotypic modulation might con-
tribute to matrix degradation within AAAs (Figure 5). How-
ever, it is also possible that this induction of MMPs within
SMCs might initiate a beneficial remodeling process by en-
hancing SMC migration, proliferation, and extracellular
matrix deposition to stabilize the vessel wall.
DISCUSSION
The data presented in the present study have demon-
strated that MCP1KOmice are resistant to experimental an-
eurysm formation. This protective effect is preserved after
transplantation of BMCs from MCP1KO mice into irradi-
ated WT hosts. Taken together, these results indicate that
bone marrow–derived MCP1 is required for experimental
AAA formation. Mac2, MMP2, MMP9, and IL-1b expres-
sion are markedly decreased and SMaA expression is mark-
edly increased in the aortas from both global MCP1KO
mice and mice with MCP1KO bone marrow transplanted
intoWT hosts. Furthermore, MCP1 is capable of promoting
MMP expression and repressing SMC markers directly on
cultured aortic SMCs in vitro, indicating MCP1 might
play important roles by way of both cytokine and chemotac-
tic functions. Although our laboratory has only recently
been the first to report that SMC phenotypic modulationdiovascular Surgery c Volume 142, Number 6 1571
FIGURE 4. Knockout of monocyte chemotactic protein 1 (MCP1) in bone marrow cells (BMCs) decreases inflammatory markers and increases intact
elastic fibers and SMaA expression. A, Immunohistochemistry performed 14 days after elastase perfusion indicates that expression of Mac2, matrix metal-
loproteinase (MMP)2, MMP9, and interleukin 1b (IL-1b) is markedly diminished in MCP1KO/WTmice. B, This correlates with a significant increase in
elastic fibers (black) and SMaA-expressing cells.




Soccurs within AAA,5 previous studies reporting the impor-
tance of normal SMC contractile protein expression,6 and
nonbone marrow–derived MMP22 indicate MCP1’s actions
on SMCs might be important to disease progression.
It is clear from these results that MCP1 is essential for
both aneurysm formation and the corresponding changes
in SMC phenotype. However, the determination of the rel-
evance of the direct action of MCP1 on SMCs in vivo is
complicated by conflicting reports regarding whether
CCR2 is expressed on SMCs.15,16 Furthermore, MCP1
has been shown to induce tissue factor in SMCs derived
from CCR2 KO mice, indicating that CCR2 is not
required for all MCP1-dependent effects.16 CCR2 could
not be detected byWestern blotting or qPCR on our cultured
SMCs, despite a robust signal from rat spleen and monocyte
lysates, corroborating a possible CCR2-independent signal-
ing pathway in SMCs (data not shown). However, efforts to
identify a second receptor forMCP1 under physiologic con-
ditions have not produced a viable result.16 Additional study
into this area is therefore required to decipher the full
in vivo relevance of MCP1’s cytokine-like actions on
SMCs, despite the importance inferred by MMP2 knockout
studies.2 More importantly, because the current preclinical
strategies for AAA have focused heavily on targeting innate
or adaptive immune cells, identifying how MCP1 acts on
SMCs might identify a novel drug target for AAA.1572 The Journal of Thoracic and Cardiovascular SurDespite this controversy, our results have clearly demon-
strated that MCP1 produced by bone marrow–derived cell
types is required for AAA formation, SMC phenotype,
and macrophage influx in the elastase perfusion model. Fur-
thermore, a major novel and unexpected finding was that
MCP1 from non-BMC sources appears to have beneficial
effects in reducing AAA formation in that loss of MCP1 ex-
clusively in bone marrow–derived cell types (Figure 3) was
of added benefit compared with the loss of MCP1 globally.
This observation is potentially more interesting given the
resistance of tissue-resident macrophages to radiation.
Although it is not possible to rule out the partial loss of
tissue-resident macrophages after irradiation as a contribu-
tor to the observed phenotype, the results clearly imply that
the required cellular source of MCP1 is radiosensitive.
Although determining the precise mechanism of this ob-
servation will require extensive additional studies, there are
a few possible explanations, each of which might not be mu-
tually exclusive. First, there might be spatial-temporal dif-
ferences in MCP1 production in BMCs versus non-BMCs
that play a key role in AAA development and/or progres-
sion. However, the existence of a spatially or temporally
‘‘opposite’’ role for MCP1 produced by BMCs versus
non-BMCs is contraindicated by the fact that MCP1KO in
non-BMCs (WT/MCP1KO, Figure 3) did not exacerbate
AAA formation compared with WT/WT (Figure 3) orgery c December 2011
FIGURE 5. Monocyte chemotactic protein 1 (MCP1) acts on cultured aortic smooth muscle cells (SMCs) to repress SMCmarker genes and induce matrix
metalloproteinases (MMPs). Cells treated with 0 to 50 ng/mL MCP1showed a dose-dependent increase in (A) MMP2 and (B) MMP9 and coordinate with
a decrease in (C) smooth muscle myosin heavy chain (SM-MHC), (D) SM22a, and (E) SMaA. *P<.05.




Sconventional MCP1KO (Figure 1). Alternatively, it might
be the total amount of MCP1 that is critical. For example,
the production of low concentrations of MCP1 might pro-
voke a sufficient ‘‘destructive’’ response to allow remodel-
ing and/or repair of the vessel wall. In contrast, the
production of high levels of MCP1 by BMCs within the ves-
sel wall might be detrimental and lead to progressive in-
flammation and exacerbation of AAA formation, delaying
or preventing a ‘‘reparative’’ response. Given this scenario,
the data suggest bone marrow–derived cells are required for
MCP1 levels to reach a destructive threshold. In such a sce-
nario, one would expect forcing elevated production of
MCP1 in the vessel wall using an inducible, cell type-
specific promoter, to be capable of driving AAA progres-
sion in the absence of MCP1 in bone marrow–derived cells.
The role of immune cells, inflammation, and MMPs in
promoting AAA has been well documented.1 However, a re-
parative role for the monocyte/macrophage in AAA has not
been explored. Notably, the monocyte/macrophage has
been identified as a key contributor of pro-healing factors
in other diseases, including myocardial ischemia.25 Further-
more, there is evidence that these ‘‘reparative’’ macrophage
actions do not take place if ‘‘destructive’’ macrophages are
prevented from first entering.25 Although the existence of
a ‘‘reparative’’ macrophage has not been identified withinThe Journal of Thoracic and CarAAA, the results presented similarly suggest that an ideal
anti-inflammatory therapy for AAAwould not globally ab-
late all aspects of the immune response but only those most
essential for the destructive aspects of inflammation.
This study had several limitations. Although the elastase
perfusion model is acute, with AA formation within
a 2-week period, this model does mimic aspects of human
disease with a chronic inflammatory infiltrate. Moreover,
this model has led to important insights regarding the
mechanisms of aneurysms formation.1,3,4 Nevertheless, it
is important to note this model is an artificial method of
creating an aneurysm. In addition, the use of ‘‘normal’’
aorta from patients undergoing coronary artery bypass
grafting can be questioned. There might be some regional
differences in the aorta between the thoracic and
abdominal aorta. Ideally, normal abdominal aorta from
healthy age-matched patients would be a more appropriate
control; however, such tissue is difficult to obtain, and cor-
onary artery bypass grafting tissue has the advantage of
being readily available.
CONCLUSIONS
The data presented in this study indicate MCP1 is essen-
tial to the progression of AAA. Importantly, MCP1 signal-
ing plays an essential role in both macrophage influx anddiovascular Surgery c Volume 142, Number 6 1573




Ssmooth muscle phenotypic modulation within AAAs. Inter-
estingly, however, our data indicate that complete inhibition
of MCP1 might not be as beneficial to inhibiting aortic
dilation as inhibition of MCP1 only in bone marrow–
derived cells. Additional study of this phenomenon and
the identification of factors or small molecules capable of
interfering with MCP1 production selectively in bone
marrow–derived cells, might yield important insights into
the design of maximally beneficial AAA therapies.
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